# Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
Canonical URL: https://biopharmsignal.com/news/ALGS/aligos-therapeutics-presents-positive-data-at-the-easl-congress-2026
Ticker: ALGS
Company: Aligos Therapeutics
Source: Aligos Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://investor.aligos.com
## Summary

Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir Data on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented 40% of HBeAg+ participants with chronic HBV infection treated with pevifoscorvir

## Article Body
Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir Data on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented 40% of HBeAg+ participants with chronic HBV infection treated with pevifoscorvir
## Recent Company News
- 2026-06-25 13:46 EST — [Aligos Therapeutics Presents Positive Data at the EASL Congress 2026](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-presents-positive-data-at-the-easl-congress-2026) — Source: Aligos Therapeutics
- 2026-06-25 13:46 EST — [Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-announces-ten-abstracts-accepted-for-presentation-at-the-easl-congress-2026) — Source: Aligos Therapeutics
- 2026-06-25 13:46 EST — [Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-first-quarter-2026-financial-results) — Source: Aligos Therapeutics
- 2026-06-25 13:46 EST — [Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer) — Source: Aligos Therapeutics
- 2026-06-25 13:46 EST — [Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-provides-phase-2-b-supreme-study-progress-updates) — Source: Aligos Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)